Optimized CRISPR/CAS9 Delivery for Disease Model Generation
Product News Nov 27, 2015
AMSBIO has launched DNA-In® CRISPR – an innovative transfection reagent that simplifies and accelerates genome editing using large plasmids and difficult-to-transfect cells for life science researchers generating disease models.
Since its emergence, CRISPR-Cas9 technology has been rapidly adopted as a mainstream approach for performing genetic manipulation. This powerful tool has transformed the process of generating “footprint-free” cellular models for studying genetic diseases.
Using this approach, researchers can easily generate disease-relevant isogenic models to determine the impact of correcting or introducing disease-relevant mutations on cellular phenotypes in a tissue-appropriate context. However, problems have remained with certain cell types that are more resistant to transfection and for larger plasmids.
DNA-In® CRISPR has been specially formulated to enable highly efficient transfection of large plasmids (containing CAS9, guide-RNAs and reporter cassettes) particularly when using hard-to-transfect cell types. The reagent is fully chemically-defined and animal component-free leading to increased reliability and low cell toxicity.
This makes it ideally suited for many applications, including use in pre-clinical investigations, giving researchers a regulatory head start in their hunt for new therapeutics. DNA-In® CRISPR is a valuable new addition to the human and mouse genome editing kits and custom genome editing services offered by AMSBIO to quickly and simply generate disease models.